Targeting of p53 peptide analogues to anti-apoptotic Bcl-2 family proteins as revealed by NMR spectroscopy

Biochemical and Biophysical Research Communications

Volumn 443, Issue 3, 2014, Pages 882-887

  Shin, Jae Sun ^a   Ha, Ji Hyang ^a   Chi, Seung Wook ^a  

^a Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

Author keywords

Bcl 2 family proteins; Cancer therapy; MDM2; Multi targeting; NMR spectroscopy; p53 Peptide analogue; pDI; PMI

Indexed keywords

BH3 PROTEIN; NUTLIN 3; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MDM2; PROTEIN P53;

APOPTOSIS; ARTICLE; BINDING SITE; COMPLEX FORMATION; HETERONUCLEAR SINGLE QUANTUM COHERENCE; HYDROPHOBICITY; NITROGEN NUCLEAR MAGNETIC RESONANCE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN TARGETING; PROTON NUCLEAR MAGNETIC RESONANCE; TRANSACTIVATION;

BCL-2 FAMILY PROTEINS; CANCER THERAPY; MDM2; MULTI-TARGETING; NMR SPECTROSCOPY; P53 PEPTIDE ANALOGUE; PDI; PMI;

AMINO ACID SEQUENCE; APOPTOSIS; BCL-X PROTEIN; BINDING SITES; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PEPTIDES; PROTEIN BINDING; PROTEIN INTERACTION MAPPING; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84893656868     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.12.054     Document Type: Article

References (42)

1. A.L. Hopkins, J.S. Mason, and J.P. Overington Can we rationally design promiscuous drugs? Curr. Opin. Struct. Biol. 16 2006 127 136
2. X.H. Ma, Z. Shi, C. Tan, Y. Jiang, M.L. Go, B.C. Low, and Y.Z. Chen In-silico approaches to multi-target drug discovery: computer aided multi-target drug design, multi-target virtual screening Pharm. Res. 27 2010 739 749
3. J.P. Overington, B. Al-Lazikani, and A.L. Hopkins How many drug targets are there? Nat. Rev. Drug Discovery 5 2006 993 996
4. Y.J. Lee, J.H. Im, D.M. Lee, J.S. Park, S.Y. Won, M.K. Cho, H.S. Nam, Y.J. Lee, and S.H. Lee Synergistic inhibition of mesothelioma cell growth by the combination of clofarabine and resveratrol involves Nrf2 downregulation BMB Rep. 45 2012 647 652
5. A.L. Hopkins Network pharmacology: the next paradigm in drug discovery Nat. Chem. Biol. 4 2008 682 690
6. Y. Dai, and S. Grant Targeting multiple arms of the apoptotic regulatory machinery Cancer Res. 67 2007 2908 2911
7. Z. Shi, X.H. Ma, C. Qin, J. Jia, Y.Y. Jiang, C.Y. Tan, and Y.Z. Chen Combinatorial support vector machines approach for virtual screening of selective multi-target serotonin reuptake inhibitors from large compound libraries J. Mol. Graph. Model 32 2012 49 66
8. B. Vogelstein, D. Lane, and A.J. Levine Surfing the p53 network Nature 408 2000 307 310
9. K.H. Vousden, and X. Lu Live or let die: the cell's response to p53 Nat. Rev. Cancer 2 2002 594 604
10. J. Momand, G.P. Zambetti, D.C. Olson, D. George, and A.J. Levine The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation Cell 69 1992 1237 1245
11. J.D. Oliner, J.A. Pietenpol, S. Thiagalingam, J. Gyuris, K.W. Kinzler, and B. Vogelstein Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53 Nature 362 1993 857 860
12. D. Alarcon-Vargas, and Z. Ronai p53-Mdm2-the affair that never ends Carcinogenesis 23 2002 541 547
13. L.T. Vassilev, B.T. Vu, B. Graves, D. Carvajal, F. Podlaski, Z. Filipovic, N. Kong, U. Kammlott, C. Lukacs, C. Klein, N. Fotouhi, and E.A. Liu In vivo activation of the p53 pathway by small-molecule antagonists of MDM2 Science 303 2004 844 848
14. M. Liu, C. Li, M. Pazgier, C. Li, Y. Mao, Y. Lv, B. Gu, G. Wei, W. Yuan, C. Zhan, W.Y. Lu, and W. Lu D-peptide inhibitors of the p53-MDM2 interaction for targeted molecular therapy of malignant neoplasms Proc. Natl. Acad. Sci. U.S.A. 107 2010 14321 14326
15. M. Pazgier, M. Liu, G. Zou, W. Yuan, C. Li, J. Li, J. Monbo, D. Zella, S.G. Tarasov, and W. Lu Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX Proc. Natl. Acad. Sci. U.S.A. 106 2009 4665 4670
16. C. Li, M. Pazgier, C. Li, W. Yuan, M. Liu, G. Wei, W.Y. Lu, and W. Lu Systematic mutational analysis of peptide inhibition of the p53-MDM2/MDMX interactions J. Mol. Biol. 398 2010 200 213
17. P.H. Kussie, S. Gorina, V. Marechal, B. Elenbaas, J. Moreau, A.J. Levine, and N.P. Pavletich Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain Science 274 1996 948 953
18. M.H. Kang, and C.P. Reynolds Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy Clin. Cancer Res. 15 2009 1126 1132
19. H.R. Kim, Y.M. Heo, K.I. Jeong, Y.M. Kim, H.L. Jang, K.Y. Lee, C.Y. Yeo, S.H. Kim, H.K. Lee, S.R. Kim, E.G. Kim, and J.K. Choi FGF-2 inhibits TNF-alpha mediated apoptosis through upregulation of Bcl2-A1 and Bcl-xL in ATDC5 cells BMB Rep. 45 2012 287 292
20. G. Lessene, P.E. Czabotar, and P.M. Colman BCL-2 family antagonists for cancer therapy Nat. Rev. Drug Discovery 7 2008 989 1000
21. K.M. Chung, and S.W. Yu Interplay between autophagy and programmed cell death in mammalian neural stem cells BMB Rep. 46 2013 383 390
22. B. Qin, B. Xiao, D. Liang, Y. Li, T. Jiang, and H. Yang MicroRNA let-7c inhibits Bcl-xl expression and regulates ox-LDL-induced endothelial apoptosis BMB Rep. 45 2012 464 469
23. T. Oltersdorf, S.W. Elmore, A.R. Shoemaker, R.C. Armstrong, D.J. Augeri, B.A. Belli, M. Bruncko, T.L. Deckwerth, J. Dinges, P.J. Hajduk, M.K. Joseph, S. Kitada, S.J. Korsmeyer, A.R. Kunzer, A. Letai, C. Li, M.J. Mitten, D.G. Nettesheim, S. Ng, P.M. Nimmer, J.M. O'Connor, A. Oleksijew, A.M. Petros, J.C. Reed, W. Shen, S.K. Tahir, C.B. Thompson, K.J. Tomaselli, B. Wang, M.D. Wendt, H. Zhang, S.W. Fesik, and S.H. Rosenberg An inhibitor of Bcl-2 family proteins induces regression of solid tumours Nature 435 2005 677 681
24. N. Bharatham, S.W. Chi, and H.S. Yoon Molecular basis of Bcl-X(L)-p53 interaction: insights from molecular dynamics simulations PLoS ONE 6 2011 e26014
25. J.H. Ha, E.Y. Won, J.S. Shin, M. Jang, K.S. Ryu, K.H. Bae, S.G. Park, B.C. Park, H.S. Yoon, and S.W. Chi Molecular mimicry-based repositioning of nutlin-3 to anti-apoptotic Bcl-2 family proteins J. Am. Chem. Soc. 133 2011 1244 1247
26. H. Xu, H. Ye, N.E. Osman, K. Sadler, E.Y. Won, S.W. Chi, and H.S. Yoon The MDM2-binding region in the transactivation domain of p53 also acts as a Bcl-X(L)-binding motif Biochemistry 48 2009 12159 12168
27. J.H. Ha, J.S. Shin, M.K. Yoon, M.S. Lee, F. He, K.H. Bae, H.S. Yoon, C.K. Lee, S.G. Park, Y. Muto, and S.W. Chi Dual-site interactions of p53 protein transactivation domain with anti-apoptotic Bcl-2 family proteins reveal a highly convergent mechanism of divergent p53 pathways J. Biol. Chem. 288 2013 7387 7398
28. J.S. Shin, J.H. Ha, F. He, Y. Muto, K.S. Ryu, H.S. Yoon, S. Kang, S.G. Park, B.C. Park, S.U. Choi, and S.W. Chi Structural insights into the dual-targeting mechanism of Nutlin-3 Biochem. Biophys. Res. Commun. 420 2012 48 53
29. A.M. Petros, A. Medek, D.G. Nettesheim, D.H. Kim, H.S. Yoon, K. Swift, E.D. Matayoshi, T. Oltersdorf, and S.W. Fesik Solution structure of the antiapoptotic protein bcl-2 Proc. Natl. Acad. Sci. U.S.A. 98 2001 3012 3017
30. D.H. Lee, J.H. Ha, Y. Kim, K.H. Bae, J.Y. Park, W.S. Choi, H.S. Yoon, S.G. Park, B.C. Park, G.S. Yi, and S.W. Chi Interaction of a putative BH3 domain of clusterin with anti-apoptotic Bcl-2 family proteins as revealed by NMR spectroscopy Biochem. Biophys. Res. Commun. 408 2011 541 547
31. B.R. Kang, H. Kim, S.H. Nam, E.Y. Yun, S.R. Kim, M.Y. Ahn, J.S. Chang, and J.S. Hwang CopA3 peptide from Copris tripartitus induces apoptosis in human leukemia cells via a caspase-independent pathway BMB Rep. 45 2012 85 90
32. E. Lee, K.W. Jeong, J. Lee, A. Shin, J.K. Kim, J. Lee, D.G. Lee, and Y. Kim Structure-activity relationships of cecropin-like peptides and their interactions with phospholipid membrane BMB Rep. 46 2013 282 287
33. A.V. Follis, J.E. Chipuk, J.C. Fisher, M.K. Yun, C.R. Grace, A. Nourse, K. Baran, L. Ou, L. Min, S.W. White, D.R. Green, and R.W. Kriwacki PUMA binding induces partial unfolding within BCL-xL to disrupt p53 binding and promote apoptosis Nat. Chem. Biol. 9 2013 163 168
34. 15N resonance assignments of a Bcl-xL/bad peptide complex J. Biomol. NMR 32 2005 260
35. F. Delaglio, S. Grzesiek, G.W. Vuister, G. Zhu, J. Pfeifer, and A. Bax NMRPipe: a multidimensional spectral processing system based on UNIX pipes J. Biomol. NMR 6 1995 277 293
36. C. Dominguez, R. Boelens, and A.M. Bonvin HADDOCK: a protein-protein docking approach based on biochemical or biophysical information J. Am. Chem. Soc. 125 2003 1731 1737
37. M. Sattler, H. Liang, D. Nettesheim, R.P. Meadows, J.E. Harlan, M. Eberstadt, H.S. Yoon, S.B. Shuker, B.S. Chang, A.J. Minn, C.B. Thompson, and S.W. Fesik Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis Science 275 1997 983 986
38. W.L. DeLano The PyMOL Molecular Graphics System 2002 PyMOL, DeLano Scientific
39. S.M. Picksley, B. Vojtesek, A. Sparks, and D.P. Lane Immunochemical analysis of the interaction of p53 with MDM2;-fine mapping of the MDM2 binding site on p53 using synthetic peptides Oncogene 9 1994 2523 2529
40. L.T. Vassilev MDM2 inhibitors for cancer therapy Trends Mol. Med. 13 2007 23 31
41. K. Kojima, M. Konopleva, I.J. Samudio, W.D. Schober, W.G. Bornmann, and M. Andreeff Concomitant inhibition of MDM2 and Bcl-2 protein function synergistically induce mitochondrial apoptosis in AML Cell Cycle 5 2006 2778 2786
42. R. Stoll, C. Renner, S. Hansen, S. Palme, C. Klein, A. Belling, W. Zeslawski, M. Kamionka, T. Rehm, P. Muhlhahn, R. Schumacher, F. Hesse, B. Kaluza, W. Voelter, R.A. Engh, and T.A. Holak Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53 Biochemistry 40 2001 336 344